The 15 most recent market catalysts affecting $LH, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Neutral
Impact 65
Labcorp Reaffirms 2026–2029 Long-Term Outlook Following CMS Preliminary Medicare Payment Rate Release; Expects Compound Annual Adj EPS Growth Of 8.5%-11.5% In 2026-2029
Labcorp's 8-K filing addresses the recent release of preliminary CMS Clinical Laboratory Fee Schedule payment rates for 2027-2029. The company views these rates as potentially dama…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $365
Truist Securities analyst David Macdonald maintained a 'Buy' rating on Labcorp Holdings (LH) and raised the price target from $350 to $365. This action signals continued analyst co…
Sep 11, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Labcorp Holdings, Raises Price Target to $380
UBS analyst Kevin Caliendo has maintained a 'Buy' rating on Labcorp Holdings (LH) and raised the price target from $361 to $380. This action signals continued confidence from a pro…
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 75
Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029
Labcorp's 8-K filing details its comprehensive growth strategy and long-term financial forecasts through 2029, including reaffirming its 2026 financial guidance. This is significan…
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 75
Labcorp Provides Long-Term Outlook Through 2029, With 5%-8% Revenue CAGR And 8.5%-11.5% Adj EPS CAGR
Labcorp's 8-K filing announces a long-term outlook through 2029, projecting a 5%-8% revenue CAGR and an 8.5%-11.5% adjusted EPS CAGR, alongside reaffirming its full-year 2026 guida…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 75
Labcorp Acquires MLM Medical Labs; Financial Terms Not Disclosed
Labcorp (LH) has acquired MLM Medical Labs, a leading global central and specialty laboratory provider with operations in the US, Germany, and South Africa. This acquisition is sig…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 65
Labcorp Announces Enhancements To Digital Experience Of Labcorp Global Trial Connect, Its Portfolio Of Clinical Trial Services, Data And Technology That Enhances And Accelerates Delivery
This announcement is a moderate corporate catalyst for Labcorp (LH) as it directly enhances their core clinical trial services. The improved digital experience could lead to increa…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 75
Labcorp Announces FDA Approval Of PGDx elio Tissue Complete CDx As Companion Diagnostic To Identify Advanced Melanoma Patients With BRAF V600E/K Variants
The FDA approval of Labcorp's PGDx elio Tissue Complete CDx as a companion diagnostic for advanced melanoma patients with BRAF V600E/K variants is a clear positive for Labcorp, enh…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Labcorp Holdings, Raises Price Target to $360
JP Morgan's analyst Lisa Gill has reaffirmed a positive stance on Labcorp Holdings by maintaining an 'Overweight' rating and raising the price target from $330 to $360. This action…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Labcorp Holdings, Raises Price Target to $338
Morgan Stanley's analyst Ricky Goldwasser has maintained an 'Overweight' rating on Labcorp Holdings (LH) and raised the price target from $308 to $338. This action signals continue…
Jul 31, 2026
Market Technicals
Bullish
Impact 55
Truist Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $350
Truist Securities analyst David Macdonald maintained a 'Buy' rating on Labcorp Holdings (LH) and raised the price target from $320 to $350. This action signals increased confidence…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
Labcorp Holdings Raises FY2026 Adj EPS Guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 Est; Raises FY2026 Sales Guidance from $14.650B-$14.800B to $14.710B-$14.827B vs $14.707B Est
Labcorp Holdings (LH) filed an 8-K to announce an upward revision to its fiscal year 2026 adjusted EPS and sales guidance. The new EPS range of $18.10-$18.55 is higher than the pri…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
Laboratory Corp Q2 Adj. EPS $4.99 Beats $4.78 Estimate, Sales $3.731B Beat $3.711B Estimate
Laboratory Corp (LH) announced its Q2 earnings, significantly surpassing analyst expectations for both adjusted EPS and sales. The adjusted EPS of $4.99 beat the $4.78 estimate by …
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
B of A Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $320
B of A Securities analyst Michael Ryskin has maintained a 'Buy' rating on Labcorp Holdings (LH) and raised the price target from $300 to $320. This action signals continued confide…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
Baird Maintains Outperform on Labcorp Holdings, Raises Price Target to $338
Baird analyst Eric Coldwell has maintained an 'Outperform' rating on Labcorp Holdings (LH) and raised the price target from $335 to $338. This action signals continued confidence i…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.